focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

Thu, 04th Apr 2024 17:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Artemis Resources Ltd - gold, copper and lithium-focused exploration company with projects in Western Australia - Updates on Karratha gold project exploration programme in West Pilbara, Western Australia. Says Lulu Creek will be drill tested in the third quarter of 2024. Adds that programme of works is submitted and approved, with heritage clearance application underway.

----------

Develop North PLC - investor in residential and commercial property sector - Starts share buyback programme of up to GBP500,000. The programme is set to end on June 30 and could be terminated earlier.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Raises GBP51,670 via issuing 5.2 million retail offer shares at a price of 1 pence each. Applies to the London Stock Exchange for the admission of a total of 152.5 million new shares to trading on AIM, comprising of 79.4 million placing shares, 5.6 million subscription shares and 62.3 million initial consideration shares

----------

Genflow Biosciences PLC - London-based biotechnology company focused on longevity - Raises GBP715,000 via its broker Capital Plus Partners by placing 57.2 million shares. Chief Executive Officer Eric Leire invested GBP50,000 personally in the placing, the company says.

----------

Insig AI PLC - London-based data science and machine learning firm - Agrees to a GBP250,000 equity funding facility with Executive Chair Richard Bernstein, which will allow him to subscribe for up to around 1.3 million new shares at 20 pence per share until the end of August.

----------

Northcoders Group PLC - Manchester-based software coding training provider - Launches part-time business-to-costumer software development bootcamp that aims to make careers in tech more accessible. The virtual course will start in mid-July and has been created due to demand for alternative structures, Northcoders says. Chief Executive Officer Chris Hill says: "Not only is this in line with the group's strategy to address the nation's widening digital skills, but it embodies our commitment to inclusivity and flexibility, ensuring that anyone who is interested in the opportunity to work in the ever-growing UK technology market can pursue their ambitions, regardless of their schedule or background."

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Raises GBP1.2 million via issuing 11.7 million fundraising shares at the placing price of 10p per share.

----------

Schroder BSC Social Impact Trust PLC - investment firm focused on positive social impact as well as long-term capital growth and income - Announces GBP5 million commitment to Savills IM Simplify Affordable Homes Ltd Partnership, which will lie within Schroder's High Impact Housing asset class allocation. "The UK continues to face a housing crisis with an acute lack of social and affordable housing and this fund will deliver homes for lower income households and people currently in need of social housing in areas in most need. The SAH management team have a strong track record, with over 30 years' expertise and deep sector knowledge with long standing housing association relationship. We believe they are well-placed to deliver high quality financial and impact returns through providing affordable housing at-scale," says Jeremy Rogers, chief investment officer of Big Society Capital, portfolio manager of Schroder BSC.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.